
Allarity Therapeutics Completes Additional Private Equity Financing

I'm PortAI, I can summarize articles.
Allarity Therapeutics completed an additional private equity financing, raising $250,000 through the sale of 255,103 common shares at $0.98 per share. The funds will be used for general corporate purposes and working capital. The company relies on exempt equity financings due to financial challenges, including no revenue and operational losses. Analysts have mixed ratings on ALLR stock, with a Buy rating and a $9.25 price target, but Spark's AI Analyst rates it as Underperform due to high-risk factors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

